ZYBERNO
Stock Report
Updated Aug 23, 2026

20/20 BIOLABS, INC. (AIDX)

NASDAQ

$0.55

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
15.0/100
POOR BUSINESS
20/20 BIOLABS, INC. (AIDX) scores 15/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.71x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-158.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

20/20 BIOLABS, INC. (AIDX) stock report — Zyberno Score 15/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.55
Market Cap:$5.98M

Valuation Multiples (3)

P/B Ratio:3.69x
P/S Ratio:2.92x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.01M
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:2.5%
Fundamental Growth Rate (g):-4.0%

Margin Analysis (1)

Ebitda Margin:-159.9%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.99x
Quick Ratio:1.95x
Cash Ratio:1.78x

Leverage Analysis (3)

Debt To Equity Ttm:0.71x
Debt-to-Equity Ratio:0.71x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-12.23x
Times Interest Earned:-12.23

Capital Structure (4)

Working Capital:2,524,387.00
Cash And Cash Equivalents:4,546,140.00
Long Term Debt:$379.72K
Net Debt:-$3.97M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$2.05M
Cost Of Revenue Ttm:$1.44M

Profitability Breakdown (2)

$604.54K-$3.33M

Bottom Line Performance (3)

-$3.74M
Income Before Tax:$0.00
Ebitda Ttm:-3,270,879.00

Operating Expenses (5)

Operating Expenses:1,548,950.00
R And D Expense:257,632.00
Sga Expense:1,291,318.00
Income Tax Expense:$0.00
Interest Expense:272,245.00

Expense Ratios (3)

R And D To Revenue Percentage:35.3%
Sga To Revenue Percentage:176.8%
Ebitda Margin:-159.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.12M
Current Assets:$5.08M
Ppe Net:540,451.00
Goodwill:0.00
Intangible Assets:$205.99K

Liability Structure (4)

Total Liabilities:2,963,877.00
Current Liabilities:2,551,236.00
Long Term Debt:$379.72K
Short Term Debt:$192.73K

Equity & Capital (3)

Equity:$1.62M
Retained Earnings:-$36.93M
Common Stock:50,000,000.00

Working Capital Items (3)

Accounts Receivable:291,486.00
Inventory:111,036.00
Accounts Payable:1,026,809.00

Special Items (2)

Contract Liabilities:499,957.00
Stock Based Compensation:128,440.00
C. Cash Flow Analysis

Operating Activities (2)

-$1.92M$0.00

Investment Activities (1)

Investing Cash Flow:-$5.35K

Financing Activities (3)

Financing Cash Flow:$4.49M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:59,992.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.35

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.19
Operating Cash Flow Per Share:-$0.18

Book Value & Capital (2)

Book Value Per Share:$0.15
Cash Per Share:0.42

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.34x
Working Capital Turnover Ttm:0.81x

Receivables Management (2)

Receivables Turnover Ttm:7.02x
Days Sales Outstanding Ttm:52.02

Inventory Management (2)

Inventory Turnover Ttm:12.97x
Days Inventory Outstanding Ttm:28.13

Payables & Cash Cycle (2)

Days Payable Outstanding:260.16
Cash Conversion Cycle:-180.01
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.5%
Fundamental Growth Rate (g):-4.0%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:AIDX
Company Name:20/20 BIOLABS, INC.
Sector:Unknown
Industry:Services-Testing Laboratories
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:10.79M
Shares Outstanding Basic:10.79M
Shares Outstanding Diluted:10.79M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 03:41:07 UTC
Data Timestamp:2026-08-21T19:51:59.516704
Scroll to Top